As of November 6, 2026, Regentis Biomaterials Ltd. is a publicly traded company (NYSE: RGNT); its largest reported holder is Rosalind Advisors, Inc., with 9.9% on Schedule 13G of August 13, 2026 (Schedule 13G, August 13, 2026).
Is this your company?
About to sign with, pay or invest in Regentis Biomaterials Ltd.? See the free Snapshot first.
Free to see. No signup.
Is Regentis Biomaterials Ltd. a real, registered company?
- Regentis Biomaterials LTD. files with the SEC under CIK 1912966 (its SEC filings).
- Its shares are listed under the ticker RGNT on NYSE (SEC company record).
- Incorporated in L3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under REGENTIS BIOMATERIALS LTD. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Rosalind Advisors, Inc. (filed 2026-08-13).
Who are Regentis Biomaterials Ltd.'s owners and officers?
Regentis Biomaterials Ltd.: industry Orthopedic, Prosthetic & Surgical Appliances & Supplies (Schedule 13G, 2026-08-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-06-25)
- : Executive Officer (Form D, 2026-06-25)
- : Executive Officer (Form D, 2026-06-25)
- : Executive Officer (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
- : Director (Form D, 2026-06-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-13 | Rosalind Advisors, Inc. | 9.9% |
| Schedule 13G, 2026-02-17 | Dr. Ehud Geller | 23.2% |
Questions about who owns Regentis Biomaterials Ltd.
Who owns Regentis Biomaterials Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of Regentis Biomaterials Ltd.: Dr. Ehud Geller (23.2%, Schedule 13G, filed 2026-02-17) and Rosalind Advisors, Inc. (9.9%, Schedule 13G, filed 2026-08-13).
Who are the largest shareholders of Regentis Biomaterials Ltd.?
By the share each holder's latest filing reports, the largest holders of Regentis Biomaterials Ltd. on this page are Dr. Ehud Geller (23.2%) and Rosalind Advisors, Inc. (9.9%).
When did Dr. Ehud Geller buy into Regentis Biomaterials Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Dr. Ehud Geller on this page is the Schedule 13G, filed 2026-02-17, reporting 23.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Regentis Biomaterials Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Regentis Biomaterials Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Regentis Biomaterials Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Regentis Biomaterials Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 130,465 shares (2.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 3, 2026-03-18).
- , a director: 128,666 shares (2.5% of shares outstanding) (Form 3, 2026-03-18).
Shares outstanding: 5,179,378 as of 2025-12-31, from the company's latest SEC cover page.
How much has Regentis Biomaterials Ltd. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-06-25 | $6.50M | $6.50M |
Latest IPO step: Regentis Biomaterials Ltd. filed to go public (F-1, 2026-07-08).
IPO filings: F-1, 2026-07-08, RW, 2026-06-15, F-1/A, 2026-06-09, F-1, 2026-05-01, F-1/A, 2025-10-24; ticker RGNT on NYSE American.
Keep reading
More on Regentis Biomaterials Ltd. and the records around it.
Regentis Biomaterials Ltd. elsewhere on the record
- 5%+ stake filings Aug 2026
- IPO filing Jul 2026
- Form D filing Jun 2026
Companies that share a holder
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/regentis-biomaterials